Oculis’ (OCS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Oculis (NASDAQ:OCS) in a research note released on Wednesday, Benzinga reports. HC Wainwright currently has a $30.00 price target on the stock.

Oculis Trading Down 0.9 %

Shares of OCS stock opened at $15.80 on Wednesday. The stock has a 50-day simple moving average of $12.97 and a 200 day simple moving average of $12.24. The stock has a market capitalization of $639.96 million, a P/E ratio of -8.88 and a beta of 0.30. Oculis has a fifty-two week low of $9.05 and a fifty-two week high of $16.70. The company has a quick ratio of 5.27, a current ratio of 5.27 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last posted its quarterly earnings data on Tuesday, August 27th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.13). Oculis had a negative net margin of 7,679.05% and a negative return on equity of 61.33%. The business had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.28 million. On average, sell-side analysts expect that Oculis will post -2.19 earnings per share for the current fiscal year.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.